<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200721048159N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-04-10</date_registration>
      <primary_sponsor>Khoram-Abad University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the Effect of Pomegranate and Turmeric Mouthwash on Oral Mucositis Due to Chemotherapy</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the Effect of Using Mouthwash Solution Containing Hydroalcoholic Extract of Pomegranate and Turmeric on Oral Mucositis Due to Chemotherapy in Cancer Patients, a Triple blind, Randomized, Controlled Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-05-17</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/55134</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Samples are used by stratified random blocking method (classes are intended to match the two groups in terms of disease grades so that patients with grade 1 and 2 in one class and patients with grade 3 and 4 in the other class) to two) An equal group of control and intervention will be assigned. The method of allocating samples to the two groups will be that considering the mucosal grade as a class, the method of 4 random blocks will be used to assign patients to two groups A (intervention) and group B (control). To do this, first write a list of blocks and assign numbers to them. (AABB (1) - ABAB (2) -ABBA (3) -BBAA (4) - BABA (5) - BAAB (6)) Then using From the table of random numbers and randomly selected numbers between 1 and 6 and finally the list of treatment allocation will be formed based on a sequence of letters A and B, Blinding description: This is a  Triple-Blind Study and the blinding method is such that the researcher and the participating patients and data analyst will be unaware of which participant is in which group. In order to blind the researcher, random grouping of participants and prescribing mouthwash to them will be assigned to one of the ward doctors or nurses who has no role in the trial. In order to blind the participating patients, mouthwash containing extract and placebo mouthwash will taste as much as possible. And will have a similar appearance and will be prescribed in identical bottles. None of the members of the Data Safety and Supervision Committee, as well as the person evaluating the outcome and analyzing the data, will have a role in the randomization and use of mouthwash by participating patients and will not be informed which mouthwash each patient will use.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Oral mucositis due to antineoplastic therapy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group Herbal mouthwash containing 6.25% hydroalcoholic extract of pomegranate peel and 0.1% hydroalcoholic extract of turmeric, once every 6 hours, 30 drops in water to reach a volume of 10 ml and hold in the mouth for 2 minutes and then gargle They will swallow. The patients will receive herbal mouthwash for a week in addition to routine treatment. Intervention 2: Control group: The control group poured 30 drops of placebo into the mouth every 6 hours until it reached a volume of 10 ml and was kept in the mouth for 2 minutes, then gargled and swallowed.The patients will receive placebo mouthwash for a week in addition to routine treatment.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Forouzan Ahmadpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kamalvand, 4 km of Khorramabad road</address>
        <city>Khoramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>12467865432453</zip>
        <telephone>+98 66 3312 0239</telephone>
        <email>ahmadpourforoz@yahoo.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Forouzan Ahmadpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kamalvand, 4 km of Khorramabad road</address>
        <city>Khoramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>12467865432453</zip>
        <telephone>+98 66 3312 0239</telephone>
        <email>ahmadpourforoz@yahoo.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients in the age range of 18 to 65 years
Cancer patients with chemotherapy-induced oral inflammation
Patients are able to complete a questionnaire and collaborate with the researcher
Absence of serious dental problems or teeth damaging the oral mucosa or sharp fillings
Do not use dentures
Do not use anti-inflammatory and other mouthwash solutions during research
No other systemic diseases
No history of smoking, drugs and alcohol
No oral candidiasis (fungus) or herpes simplex (virus)
Do not use cryotherapy for six weeks before the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Dissatisfaction with participating in the study
Participate in another clinical trial at the same time
History of allergies to turmeric and pomegranate, lidocaine, antacids, diphenhydramine and dexamethasone
Inability of the patient to implement the treatment protocol
Patient death due to failure to respond to anticancer therapy
Combination therapies such as radiation therapy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K12.31</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Oral mucositis (ulcerative) due to antineoplastic therapy</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group Herbal mouthwash containing 6.25% hydroalcoholic extract of pomegranate peel and 0.1% hydroalcoholic extract of turmeric, once every 6 hours, 30 drops in water to reach a volume of 10 ml and hold in the mouth for 2 minutes and then gargle They will swallow. The patients will receive herbal mouthwash for a week in addition to routine treatment.</i_keyword>
      <i_keyword>Control group: The control group poured 30 drops of placebo into the mouth every 6 hours until it reached a volume of 10 ml and was kept in the mouth for 2 minutes, then gargled and swallowed.The patients will receive placebo mouthwash for a week in addition to routine treatment.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Grade  of mucositis based on WHO scale. Timepoint: Evaluation of grade of mucositis at the beginning of the study, 7 and 14 days after mouthwash containing pomegranate and turmeric extract. Method of measurement: Standard questionnaire and patient examination.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Khorramabad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-03-09</approval_date>
        <contact_name>Ethics Committee of Lorestan University of Medical Sciences</contact_name>
        <contact_address>Naser Khosrow Square, Roudaki St., Chaghervand Alley, No. 10 khorram abad Lorestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
